Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Can J Diabetes. 2014 Oct 22;39(1):73–77. doi: 10.1016/j.jcjd.2014.06.005

Table 2.

Visual acuity (VA) and Central subfield macular thickness (CST) at the initial and final follow-up

Oral anti-diabetic agents group (N=46) Insulin therapy group (N=49) p
VA Initial 20/61 ± 20/39 20/76 ± 20/55 0.239
Final 20/49 ± 20/36 20/56 ± 20/60 0.489
CST (μm) Initial 454.7 ± 142.8 471.5 ± 145.3 0.586
Final 354.9 ± 120.3 368.4 ± 122.9 0.591